Ulipristal Acetate for Emergency Contraception

被引:15
|
作者
Snow, Sara E. [1 ]
Melillo, Stephanie N. [1 ]
Jarvis, Courtney I. [2 ]
机构
[1] Biogen Idec Massachusetts Coll Pharm & Hlth Sci, Sch Pharm, Worcester, MA USA
[2] Massachusetts Coll Pharm & Hlth Sci, Sch Pharm, Worcester, MA USA
关键词
CDB-2914; ella; emergency contraception; ulipristal acetate; PROGESTERONE-RECEPTOR MODULATORS;
D O I
10.1345/aph.1P704
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of data of ulipristal acetate, a new emergency contraceptive approved for use up to 120 hours after unprotected intercourse. DATA SOURCES: Articles pertaining to the topic were identified and reviewed through searches of PubMed (1994-March 2011) and clinicaltrials.gov, using the key terms ulipristal and CDB-2914. Ella approval documents were obtained and reviewed from Drugs@FDA on the Food and Drug Administration (FDA) Web site. STUDY SELECTION AND DATA EXTRACTION: All published data and FDA approval documents examining pharmacologic, pharmacokinetic, and clinical studies related to ulipristal acetate as an emergency contraceptive were evaluated. Selected studies included 3 randomized trials and 1 meta-analysis. DATA SYNTHESIS: Ulipristal acetate is a progesterone agonist/antagonist emergency contraceptive approved for the prevention of pregnancy to be taken as soon as possible, within 120 hours after unprotected intercourse or a known or suspected contraceptive failure. Based upon results of the Phase 3 clinical trials used to obtain approval, ulipristal acetate administration was at least as effective as levonorgestrel in the reduction of pregnancy rate when studied alone after unprotected intercourse and when taken up to 120 hours after unprotected intercourse. Commonly reported adverse effects associated with ulipristal acetate in trials included headache, breast tenderness, nausea, and abdominal pain. CONCLUSIONS: Ulipristal acetate is effective as an emergency contraceptive for up to 120 hours after unprotected intercourse. Because ulipristal is available only via prescription, it may be covered by insurance. However, the additional factors of travel expenses and time to make and attend a physician appointment must be taken into account when considering use of ulipristal as an emergency contraceptive. Due to the similarity of its structure to mifepristone, controversy regarding ulipristal's mechanism of action has arisen.
引用
收藏
页码:780 / 786
页数:7
相关论文
共 50 条
  • [21] Ulipristal Acetate: Critical Review About Endometrial and Ovulatory Effects in Emergency Contraception
    Bruno Mozzanega
    Salvatore Gizzo
    Stefania Di Gangi
    Erich Cosmi
    Giovanni Battista Nardelli
    [J]. Reproductive Sciences, 2014, 21 : 678 - 685
  • [22] Use of ulipristal acetate and levonorgestrel for emergency contraception: a follow-up study
    Baird, Aisling Susan
    Trussell, James
    Webb, Anne
    [J]. JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE, 2015, 41 (02): : 116 - 121
  • [23] Ulipristal Acetate: Critical Review About Endometrial and Ovulatory Effects in Emergency Contraception
    Mozzanega, Bruno
    Gizzo, Salvatore
    Di Gangi, Stefania
    Cosmi, Erich
    Nardelli, Giovanni Battista
    [J]. REPRODUCTIVE SCIENCES, 2014, 21 (06) : 678 - 685
  • [24] Pregnancy outcome after failure of emergency contraception with ulipristal acetate - an observational study
    Hoeltzenbein, M.
    Wagner, J. K.
    Schaefer, C.
    Dathe, K.
    [J]. EUROPEAN JOURNAL OF HUMAN GENETICS, 2020, 28 (SUPPL 1) : 180 - 180
  • [25] Availability of ulipristal acetate: A secret shopper survey of pharmacies in a metropolitan area on emergency contraception
    French, Valerie A.
    Mattingly, Tateum L.
    Rangel, Ariana V.
    Shelton, Annie U.
    [J]. JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2019, 59 (06) : 832 - 835
  • [26] Ulipristal Acetate Taken 48-120 Hours After Intercourse for Emergency Contraception
    Fine, Paul
    Mathe, Henri
    Ginde, Savita
    Cullins, Vanessa
    Morfesis, Johanna
    Gainer, Erin
    [J]. OBSTETRICS AND GYNECOLOGY, 2010, 115 (02): : 257 - 263
  • [27] Emergency contraception failure and ulipristal acetate exposure in pregnant women: First concerns and outcomes
    Ozturk, Z.
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2017, 390 : S75 - S76
  • [28] The rationale for use of Ulipristal Acetate as first line in emergency contraception: biological and clinical evidence
    Glasier, Anna
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2014, 30 (10) : 688 - 690
  • [29] Pregnancy Outcomes Following Ulipristal Acetate Emergency Contraception Failure: A Report of Five Cases
    Ozturk, Zeynep
    Akgul, Emine
    [J]. FETAL AND PEDIATRIC PATHOLOGY, 2017, 36 (03) : 213 - 219
  • [30] Double dosing ulipristal acetate emergency contraception for individuals with obesity: a randomised crossover trial
    Edelman, Alison
    Hennebold, Jon D.
    Bond, Kise
    Lim, Jeong Y.
    Cherala, Ganesh
    Blue, Steven W.
    Kraft, Shawn P.
    Erikson, David W.
    Archer, David
    Jensen, Jeffery
    [J]. BMJ SEXUAL & REPRODUCTIVE HEALTH, 2024,